2022: A TherapeutAix Roundup
As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting on the return of in-person events, the advancements in medicine and the successes of our client projects. Here are our top highlights: Events 2022 saw a welcomed return to in-person events, and we had […]
What’s it like to work with us?
What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our website, here’s how a typical client of ours may use us in support of their R&D project. Initial contact We usually start with an initial video call to get to know each other, understand […]
One Project, Many Customers
In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets disease, target a mechanism, and identify and optimise a molecule that can modulate the mechanism to treat the disease. Theoretically, it would work that way if not for different stakeholders expecting different data to justify […]
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D, to provide our collective thoughts on the use and value of the pre-clinical bleomycin model in drug development for Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive lung disease with […]
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of this three-day meeting was very much on the role of collagens and other extra-cellular matrix components in health and disease. What did we learn? A lot about the basic structure and function of matrix proteins, […]
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach and our R&D network, we organise and moderate bespoke workshops for our clients. As workshops are a highly efficient and engaging means to work through scenarios and identify potential solutions, we are using them for […]
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding of common diseases. This year, we delve into whether the reverse can be true as well. What is a rare disease? In the European Union, a disease is categorised as ‘rare’ if it affects fewer […]
Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown aetiology, may offer strategic insights into IPF drug development that are similarly applicable to other indications. In this blog we look at the adoption and cost-effectiveness of two approved IPF therapies, nintedanib and pirfenidone, and […]
Happy Birthday TherapeutAix! Celebrating our third year
As TherapeutAix celebrates our three-year birthday this month, we thought it would be a great opportunity to take a look back at our achievements over the last year and share some of our top highlights, including events we’ve hosted and attended, projects we’ve worked on, and our latest publications. Welcoming new partners Following a fruitful […]
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our reflections. Despite the virtual format there was still a huge amount of information, so we have decided to limit this to just 4 take-home messages that we came away with. What’s next in COPD? When working with […]